In the GARNET trial, PTEN-deficient endometrial cancers showed improved responses when combining immune checkpoint blockade (dostarlimab) with PI3K pathway inhibitors, further suggesting that targeting PI3K compensates for the heightened oncogenic signaling due to PTEN loss [17]. Here, PIK3CA is linked to endometrial cancer.